Complement Activation, Immunogenicity, and Immune Suppression as Potential Side Eff ects of Liposomes - Harnessing Biomaterials in Nanomedicine: Preparation, Toxicity, and Applications - page 331

59. Koide, H., Asai, T., Hatanaka, K., Urakami, T., Ishii, T., Kenjo, E., Nishihara,
M., Yokoyama, M., Ishida, T., Kiwada, H., and Oku, N. (2008). Particle size-
dependent triggering of accelerated blood clearance phenomenon. Int.
J. Pharm . 362, pp. 197-200.
60. Lieberman, P. (1989). The use of antihistamines in the prevention and
treatment of anaphylaxis and anaphylactoid reactions. Singapore Med.
J . 30, pp. 290-293.
61. Lieberman, P. (1991). Anaphylactoid reactions to radiocontrast
material. Clin. Rev. Allergy 9, pp. 319-338.
62. Lipinski, C. A., Lombardo, F., Dominy, B. W., and Feeney, P. J. (1997).
Experimental and computational approaches to estimate solubility
and permeability in drug discovery and development settings. Adv.
Drug Deliv. Rev . 23, pp. 3-25.
63. Marcato, P. D., and Duran, N. (2008). New aspects of nanopharmaceutical
delivery systems. J. Nanoscience Nanotechnol . 8, pp. 1-14.
64. Masaki, T., Okada, N., Yasuda, R., and Okada, H. (1989). Assay of
complement activity in human serum using large unilamellar
liposomes. J. Immunol. Methods 123, pp. 19-24.
65. Matyas, G. R., Wassef, N. M., Rao, M., and Alving, C. R. (2000). Induction
and detection of antibodies to squalene. J. Immunol. Methods 245, pp.
1-14.
66. Meunier, F., Prentice, H. G., and Ringdén, O. (1991). Liposomal
amphotericin B (AmBisome): safety data from a phase II/III clinical
trial. J. Antimicrob. Chemother. 28 Suppl B, pp. 83-91.
67. Moghimi, S. M., Andersen, A. J., Hashem, S. H., Lettiero, B., Ahmadvand,
D., Hunter, A. C., Andresen, T. L., Hamad, I., and Szebeni, J. (2010).
Complement activation cascade triggered by PEG-PL engineered
nanomedicines and carbon nanotubes: the challenges ahead. J. Control.
Release 146, pp. 175-181.
68. Moghimi, S. M., Hamad, I., Andresen, T. L., Jörgensen, K., and Szebeni, J.
(2006). Methylation of the phosphate oxygen moiety of phospholipid-
methoxy(polyethylene glycol) conjugate prevents PEGylated liposome-
mediated complement activation and anaphylatoxin production. FASEB
J . 20, pp. 2591-2593.
69. Mold, C., and Gewurz, H. (1980). Activation of human complement
by liposomes: serum factor requirement for alternative pathway
activation. J. Immunol . 125, pp. 696-700.
70. Money-Kyrle, J. F., Bates, F., Ready, J., Gazzard, B. G., Phillips, R. H., and
Boag, F. C. (1993). Liposomal daunorubicin in advanced Kaposi's
sarcoma: a phase II study. Clin. Oncol. (R. Coll. Radiol.) 5, pp. 367-371.